137 related articles for article (PubMed ID: 17602083)
21. Effect of interferon-alpha A/D in combination with the Japanese and Chinese traditional herbal medicine juzen-taiho-to on lung metastasis of murine renal cell carcinoma.
Muraishi Y; Mitani N; Yamaura T; Fuse H; Saiki I
Anticancer Res; 2000; 20(5A):2931-7. PubMed ID: 11062703
[TBL] [Abstract][Full Text] [Related]
22. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
23. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
[TBL] [Abstract][Full Text] [Related]
24. [Renal cell carcinoma-interferon therapy, its clinical adaptation and limitations].
Noguchi S; Hosaka M
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2383-9. PubMed ID: 1952957
[TBL] [Abstract][Full Text] [Related]
25. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
[TBL] [Abstract][Full Text] [Related]
26. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
[TBL] [Abstract][Full Text] [Related]
27. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
[TBL] [Abstract][Full Text] [Related]
29. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Van Gool AR; Verkerk R; Fekkes D; Bannink M; Sleijfer S; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
Psychiatry Clin Neurosci; 2008 Oct; 62(5):597-602. PubMed ID: 18950381
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
31. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
32. Muscle and small intestinal metastasis of renal cell carcinoma markedly responsive to interferon-alpha therapy: a case report.
Sano F; Kimura R; Fujikawa N; Sugiura S; Hirai K; Ueki T; Kitami K
Hinyokika Kiyo; 2007 Sep; 53(9):635-9. PubMed ID: 17933140
[TBL] [Abstract][Full Text] [Related]
33. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
[TBL] [Abstract][Full Text] [Related]
34.
Yamamoto K; Ioroi T; Shinomiya K; Yoshida A; Harada K; Fujisawa M; Omura T; Ikemi Y; Nakagawa S; Yonezawa A; Ogawa O; Matsubara K; Iwamoto T; Nishikawa K; Hayashi S; Tohara D; Murakami Y; Motoshima T; Jono H; Yano I
Oncol Res; 2022 May; 29(1):11-23. PubMed ID: 35016744
[TBL] [Abstract][Full Text] [Related]
35. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K
Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361
[TBL] [Abstract][Full Text] [Related]
36. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
37. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
NĂ©grier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
38. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]